Natansh Modi

Flinders University

Australia

Research Interests

Explore related searches

Professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (17)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (9)

Eric Perakslis

Chief Science Officer

Duke Medicine

UNITED STATES

View details

Rebecca Venchiarutti

Head and Neck Research Fellow

Chris O'Brien Lifehouse

AUSTRALIA

View details

Ashley M Hopkins

AUSTRALIA

View details

Tammy Hoffmann

Bond University

AUSTRALIA

View details

Ross McKinnon

Professor

Flinders University

AUSTRALIA

View details

Frank Rockhold

Professor

Duke University School of Medicine

UNITED STATES

View details

Jessica Marie Logan

University of South Australia

AUSTRALIA

View details

Bradley Menz

Flinders University

AUSTRALIA

View details

Benjamin Chin‐Yee

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Natansh Modi

Research Interests

Explore related searches

Contact this professor

Articles (17)

Current safeguards, risk mitigation, and transparency measures of large language models against the generation of health disinformation

Accessibility of clinical study reports supporting medicine approvals: a cross-sectional evaluation

Health Disinformation Use Case Highlighting the Urgent Need for Artificial Intelligence Vigilance

Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration–Approved Anticancer Drugs: A Call for Systematic Data Availability

Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma

Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages

A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration

Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer

Association between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab

Association between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab

Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data

A literature review of treatment-specific clinical prediction models in patients with breast cancer

Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine

Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy

Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-trastuzumab Emtansine

Collaborators (9)

Eric Perakslis

Rebecca Venchiarutti

Ashley M Hopkins

Tammy Hoffmann

Ross McKinnon

Frank Rockhold

Jessica Marie Logan

Bradley Menz

Benjamin Chin‐Yee

Make your next move.